Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VLMVA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
37917829 ADC 2
|
|||||
| Synonyms |
ADC 2
Click to Show/Hide
|
|||||
| Organization |
GSK, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, United Kingdom.; Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow G1 1XL, United Kingdom.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
RIPK2 PROTAC
|
Payload Info | ||||
| Therapeutic Target |
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Site-specific conjugation via re-bridging.
|
|||||